Formulation Development
IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies
IONTAS Limited and FairJourney Biologics S.A recently announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a…
Micropore Appoints Technology Distributor for Japanese Market
Award-winning UK-based particle engineering specialist Micropore Technologies has just announced the appointment of the Mutual Corporation as the representative for sales….
Hovione Completes its Phase 2 Clinical Trial of the First Minocycline Ophthalmic
Hovione recently announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused….
Axol Bioscience & Censo Biotechnologies Announce Merger
Axol Bioscience Ltd and CENSO Biotechnologies recently announced that the two companies have signed a merger agreement. The new entity will become a leading provider…
ProBioGen Licenses GlymaxX Technology to Sanofi
ProBioGen AG has recently signed a commercial multi-product license agreement with Sanofi. Under such agreement, Sanofi will integrate ProBioGen’s proprietary GlymaxX technology into their product development…
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study
Timber Pharmaceuticals, Inc. recently announced 50% of patients in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) in patients with moderate-to-severe congenital ichthyosis (CI)…
FSD Pharma Enters License Agreement to Develop FDA-Approved Veterinary Drugs
FSD Pharma recently announced it has entered into a license agreement with Innovet Italia S.R.L., under which Innovet granted the company a license to use…
AC Immune Announces New Clinical Results in Down Syndrome, Plans for Future Development of Anti-Amyloid-Beta Vaccine
AC Immune SA recently announced plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and prevent the progression of Down…
Quotient Sciences: Upcoming Solubility Enhancement & Pediatric Development Webinars
Access our webinars on solubility strategies & pediatric drug development….
Vetter Establishes Office in China to Better Serve the Needs of its Growing Customer Base Worldwide
Vetter, one of the global leaders in prefilled drug-delivery systems, recently announced the opening of a new business entity in Shanghai, China…..
Vectura Expands Dry Powder Inhaler Development & Manufacturing Capabilities
Vectura Group plc, an industry leading inhalation CDMO, recently announced an expansion of its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, UK…..
Mateon Provides Update on Global Covid-19 Study
Mateon Therapeutics, Inc. recently announced it has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients, which allows for the continuing…
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
AIM ImmunoTech Inc. recently announced it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen…
Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis
Ocuphire Pharma recently announced that the results from the MIRA-1 (NCT04024891) Phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal…
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial
Aravive, Inc. recently announced it has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary…
twoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy & Safety of Two Novel Chronic Kidney Disease Treatment Candidates
twoXAR Pharmaceuticals recently announced two novel leads for the potential treatment of chronic kidney disease (CKD), TXR-1208 and TXR-1210, demonstrated significant efficacy and excellent tolerability…
Codex DNA Releases World’s First Synthetic Genomes for Emerging SARS-CoV-2 Variants
Codex DNA, Inc., recently announced the release of the world’s first full-length synthetic genomes for two emerging variants of the SARS-CoV-2 virus. The new genomes…
Ridgeback Biotherapeutics & Merck Announce Preliminary Findings From Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Merck and Ridgeback Biotherapeutics recently announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA….
Veru Receives FDA Agreement to Advance VERU-111 Into Phase 3 Study
Veru Inc. recently announced the FDA agreed in an End of Phase 2 meeting, to advance VERU-111 into a Phase 3 registration clinical study based on the clinically meaningful benefits observed with….
LEXEO Therapeutics Announces License Agreement & Consolidation of Comprehensive Preclinical Data Package
LEXEO Therapeutics recently announced it has licensed worldwide intellectual property rights and preclinical data from Adverum Biotechnologies to its….
